COSCIENS Biopharma Inc T.CSCI

Is there a glimmer of light at the end of the tunnel?

[archeo753]

Massive expenses of the merger hopefully coming to an end after this quarter. Sales weren't horrible compared to corresponding 2023 quarter.  Looks like they are focusing on PGX and Ceapro products.  Discontinuing costly AEZS pipe dreams.

"In contrast, the projected
timelines and costs to reach the next value inflection point in the pre-clinical auto-immune
modifying disease (“AIMS Biologicals”) platform and Delayed Clearance Parathyroid
Hormone ("DC-PTH", AEZS-150) fusion proteins program are increasingly challenging
and, as a result, we have made the decision to discontinue further investment in these
programs,” stated Gilles Gagnon, M.Sc., MBA, President and CEO of COSCIENS."

[Apostata]

Dear lord, has Gagnon always been described with his academic credentials or is this some sort of desperate way to show relevance?

[prophetoffactz]

With the failure of the diagnostic test and potential licensing deal they don't appear to have the cash now for AEZS's pipeline assets and have stopped development. It's back to CZO's assets but delays there. Who they can get as the new President and CEO will help tell the story as they wait for key data for the avenanthramide pill, and PGX scale-up, etc. 

[Tencents]

So why the merger  seems ceapro gave up 50 % of their assets for nothing in return 

[lscfa]

They spent $1.3M US on macimorelon pediatric trial in the qtr. Let's hope that's not repeated next quarter.